open access

Vol 82, No 3 (2014)
REVIEWS
Submitted: 2014-04-30
Accepted: 2014-04-30
Get Citation

Influence of inhaler and fine particle on efficacy of inhalation therapy in COPD

Paweł Śliwiński, Ryszarda Chazan, Piotr Dąbrowiecki, Karina Jahnz-Różyk, Robert Mróz, Michał Pirożyński
DOI: 10.5603/PiAP.2014.0035
·
Pneumonol Alergol Pol 2014;82(3):300-310.

open access

Vol 82, No 3 (2014)
REVIEWS
Submitted: 2014-04-30
Accepted: 2014-04-30

Abstract

Orally inhaled products delivered via inhalation exert their effect directly to the target organ. This allows to administer a very low dose of a drug compared with an oral route with similar clinical effect and significantly reduced toxicity. However inhalation therapy is also limited by several factors. Delivery of the desired dose of the drug to the airways depends on a type of the inhaler — pressurised metered-dose inhaler (pMDI) or dry powder inhaler (DPI), inhaler characteristics (low or high internal resistance, diameter of particles and distribution of the generated aerosol fine particles), thermal conditions of air, and ability of patient to generate sufficient inspiratory flow (for DPI) or to coordinate actuation with inhalation (for pMDI). Unlike pMDIs, DPIs are breath- -actuated, hence avoiding the need for the patient to coordinate actuation with inspiration. Furthermore, DPIs are propellant-free and do not produce the cold sensation on inhalation. Currently available DPIs vary widely in design, operating characteristics and performance. And poor inhalation technique may compromise treatment efficacy. Hence, there is a clear need for a careful selection of DPIs for different patient groups, including children, elderly patients and those with severe airway obstruction.

Abstract

Orally inhaled products delivered via inhalation exert their effect directly to the target organ. This allows to administer a very low dose of a drug compared with an oral route with similar clinical effect and significantly reduced toxicity. However inhalation therapy is also limited by several factors. Delivery of the desired dose of the drug to the airways depends on a type of the inhaler — pressurised metered-dose inhaler (pMDI) or dry powder inhaler (DPI), inhaler characteristics (low or high internal resistance, diameter of particles and distribution of the generated aerosol fine particles), thermal conditions of air, and ability of patient to generate sufficient inspiratory flow (for DPI) or to coordinate actuation with inhalation (for pMDI). Unlike pMDIs, DPIs are breath- -actuated, hence avoiding the need for the patient to coordinate actuation with inspiration. Furthermore, DPIs are propellant-free and do not produce the cold sensation on inhalation. Currently available DPIs vary widely in design, operating characteristics and performance. And poor inhalation technique may compromise treatment efficacy. Hence, there is a clear need for a careful selection of DPIs for different patient groups, including children, elderly patients and those with severe airway obstruction.

Get Citation

Keywords

inhalation therapy, dry powder inhaler, DPI, COPD, airway obstruction

About this article
Title

Influence of inhaler and fine particle on efficacy of inhalation therapy in COPD

Journal

Advances in Respiratory Medicine

Issue

Vol 82, No 3 (2014)

Pages

300-310

DOI

10.5603/PiAP.2014.0035

Bibliographic record

Pneumonol Alergol Pol 2014;82(3):300-310.

Keywords

inhalation therapy
dry powder inhaler
DPI
COPD
airway obstruction

Authors

Paweł Śliwiński
Ryszarda Chazan
Piotr Dąbrowiecki
Karina Jahnz-Różyk
Robert Mróz
Michał Pirożyński

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl